{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Glioblastoma%2C+Glioma&page=35",
    "query": {
      "condition": "Glioblastoma, Glioma",
      "page": 35
    },
    "page_size": 10
  },
  "pagination": {
    "page": 35,
    "page_size": 10,
    "total_count": 1351,
    "total_pages": 136,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Glioblastoma%2C+Glioma&page=36&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Glioblastoma%2C+Glioma&page=34&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-16T06:30:31.089Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00095771",
      "title": "Arsenic Trioxide and Radiation Therapy in Treating Young Patients With Newly Diagnosed Gliomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors"
      ],
      "interventions": [
        {
          "name": "arsenic trioxide",
          "type": "DRUG"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "3 Years to 21 Years"
      },
      "enrollment_count": 36,
      "start_date": "2004-11",
      "completion_date": "2011-01",
      "has_results": false,
      "last_update_posted_date": "2011-04-22",
      "last_synced_at": "2026-10-16T06:30:31.089Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00095771"
    },
    {
      "nct_id": "NCT03971734",
      "title": "Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "High Grade Glioma",
        "Anaplastic Astrocytoma",
        "Anaplastic Oligodendroglioma",
        "Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Regadenoson 0.05mg",
          "type": "DRUG"
        },
        {
          "name": "Regadensoson 0.1mg",
          "type": "DRUG"
        },
        {
          "name": "Regadensoson 0.2mg",
          "type": "DRUG"
        },
        {
          "name": "Regadensoson 0.4mg",
          "type": "DRUG"
        },
        {
          "name": "Regadensoson 0.7mg",
          "type": "DRUG"
        },
        {
          "name": "Regadensoson 1.0mg",
          "type": "DRUG"
        },
        {
          "name": "Regadensoson 1.4mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 7,
      "start_date": "2019-12-06",
      "completion_date": "2023-10-02",
      "has_results": false,
      "last_update_posted_date": "2023-10-06",
      "last_synced_at": "2026-10-16T06:30:31.089Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03971734"
    },
    {
      "nct_id": "NCT00795665",
      "title": "Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioma"
      ],
      "interventions": [
        {
          "name": "bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "carmustine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Davis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2008-06",
      "completion_date": "2015-12",
      "has_results": true,
      "last_update_posted_date": "2020-05-12",
      "last_synced_at": "2026-10-16T06:30:31.089Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00795665"
    },
    {
      "nct_id": "NCT02209376",
      "title": "Autologous T Cells Redirected to EGFRVIII-With a Chimeric Antigen Receptor in Patients With EGFRVIII+ Glioblastoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Patients With Residual or Reccurent EGFRvIII+ Glioma"
      ],
      "interventions": [
        {
          "name": "CART-EGFRvIII T cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2014-11-18",
      "completion_date": "2018-04-04",
      "has_results": false,
      "last_update_posted_date": "2023-06-22",
      "last_synced_at": "2026-10-16T06:30:31.089Z",
      "location_count": 2,
      "location_summary": "San Francisco, California • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02209376"
    },
    {
      "nct_id": "NCT01068782",
      "title": "Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Astrocytic Tumors"
      ],
      "interventions": [
        {
          "name": "Cabozantinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Exelixis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2010-04",
      "completion_date": "2013-10",
      "has_results": true,
      "last_update_posted_date": "2026-02-25",
      "last_synced_at": "2026-10-16T06:30:31.089Z",
      "location_count": 17,
      "location_summary": "Birmingham, Alabama • Encinitas, California • Pleasant Hill, California + 12 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Pleasant Hill",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01068782"
    },
    {
      "nct_id": "NCT02345824",
      "title": "Early-Phase Study to Assess Inhibitor Ribociclib in Patients With Recurrent Glioblastoma or Anaplastic Glioma",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioblastoma",
        "Glioma"
      ],
      "interventions": [
        {
          "name": "Ribociclib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Virginia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 3,
      "start_date": "2016-03",
      "completion_date": "2020-01",
      "has_results": false,
      "last_update_posted_date": "2018-06-07",
      "last_synced_at": "2026-10-16T06:30:31.089Z",
      "location_count": 1,
      "location_summary": "Charlottesville, Virginia",
      "locations": [
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02345824"
    },
    {
      "nct_id": "NCT00544817",
      "title": "Radiation Therapy and Temozolomide Followed by Temozolomide Plus Sorafenib for Glioblastoma Multiforme",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma Multiforme"
      ],
      "interventions": [
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Sorafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "SCRI Development Innovations, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 47,
      "start_date": "2007-04",
      "completion_date": "2010-08",
      "has_results": true,
      "last_update_posted_date": "2016-09-01",
      "last_synced_at": "2026-10-16T06:30:31.089Z",
      "location_count": 10,
      "location_summary": "Fort Myers, Florida • Gainesville, Georgia • Bethesda, Maryland + 7 more",
      "locations": [
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Gainesville",
          "state": "Georgia"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00544817"
    },
    {
      "nct_id": "NCT04541082",
      "title": "Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Central Nervous System Neoplasms",
        "Glioblastoma",
        "Gliosarcoma, Adult",
        "Anaplastic Oligodendroglioma",
        "Anaplastic Astrocytoma",
        "Pilocytic Astrocytoma",
        "Oligodendroglioma",
        "Gliomatosis Cerebri",
        "Pleomorphic Xanthoastrocytoma",
        "Anaplastic Pleomorphic Xanthoastrocytoma",
        "Diffuse Midline Glioma, H3 K27M-Mutant",
        "Ependymoma",
        "Ependymoma, Anaplastic",
        "Medulloblastoma",
        "Teratoid Rhabdoid Tumor",
        "Neuroectodermal Tumors, Primitive",
        "Neuroectodermal Tumors",
        "Anaplastic Meningioma",
        "Atypical Meningioma",
        "Choroid Plexus Neoplasms",
        "Pineal Tumor",
        "Diffuse Astrocytoma",
        "Glial Tumor"
      ],
      "interventions": [
        {
          "name": "ONC206",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jazz Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 102,
      "start_date": "2020-10-26",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2025-12-18",
      "last_synced_at": "2026-10-16T06:30:31.089Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04541082"
    },
    {
      "nct_id": "NCT00006474",
      "title": "Temozolomide and O6-benzylguanine in Treating Patients With Newly Diagnosed, Recurrent, or Progressive Anaplastic Glioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors"
      ],
      "interventions": [
        {
          "name": "O6-benzylguanine",
          "type": "DRUG"
        },
        {
          "name": "temozolomide",
          "type": "DRUG"
        },
        {
          "name": "conventional surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2001-03",
      "completion_date": "2004-08",
      "has_results": false,
      "last_update_posted_date": "2013-06-20",
      "last_synced_at": "2026-10-16T06:30:31.089Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00006474"
    },
    {
      "nct_id": "NCT00052208",
      "title": "Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Adult Giant Cell Glioblastoma",
        "Adult Glioblastoma",
        "Adult Gliosarcoma"
      ],
      "interventions": [
        {
          "name": "gefitinib",
          "type": "DRUG"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 158,
      "start_date": "2002-03",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2020-10-30",
      "last_synced_at": "2026-10-16T06:30:31.089Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00052208"
    }
  ]
}